Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Anticancer Agents : Design, Synthesis and Evaluation
| Anticancer Agents : Design, Synthesis and Evaluation |
| Autore | Chen Qiao-Hong |
| Pubbl/distr/stampa | Basel, Switzerland, : MDPI - Multidisciplinary Digital Publishing Institute, 2021 |
| Descrizione fisica | 1 electronic resource (606 p.) |
| Soggetto topico | Medicine |
| Soggetto non controllato |
benzofurans
chemical synthesis cytotoxic properties HeLa MOLT-4 K562 anticancer anti-neuroinflammation coumarin dihydroartemisinin flavonoids allene E-stereoselective regioselective anti-cancer activity cyanopyridone substituted pyridine pyridotriazine pyrazolopyridine thioxotriazopyridine anticancer activity HepG2 antitumor activity computational docking MDM2-p53 interaction xanthones yeast-based assays estrone derivatives hydrazine N-substituted pyrazoline anti-ovarian cancer topoisomerase II inhibitor kinase inhibitor antiproliferative agent urea synthesis antiproliferative activity apoptosis indoleamine 2,3-dioxygenase inhibitor anti-tumor immune modulation tryptophan metabolism taxoids βIII-tubulin P-glycoprotein drug resistance thiopene thienopyrimidinone thiazolidinone breast cancer benzofuran–pyrazole nanoparticles cytotoxic activity PARP-1 inhibition 3,6-dibromocarbazole 5-bromoindole carbazole actin migration Thienopyrimidine Pyrazole PI3Kα inhibitor quinazolin-4(3H)-one quinazolin-4(3H)-thione Schiff base antioxidant activity DFT study ortho-quinones beta-lapachone tanshione IIA PI3Ks PI3Kδ inhibitors 2H-benzo[e][1,2,4]thiadiazine 1,1-dioxide anticancer agents protein–protein interactions virtual screening mimetics drug discovery bivalency polyvalency antitumor cell cycle ovarian cancer P-MAPA IL-12 TLR signaling inflammation chemoresistance 4-(pyridin-4-yloxy)benzamide 1,2,3-triazole c-Met natural product anticancer agent zampanolide Talazoparib PARP inhibitor prodrug o-nitro-benzyl photoactivatable protecting groups salinomycin overcoming drug resistance tumor specificity synergy 5-fluorouracil gemcitabine amides/esters colchicine analogs thiocolchicine colchiceine antimitotic agents hydrates dihydropyranoindole HDAC inhibitors neuroblastoma aromatase MCF-7 NIH3T3 benzimidazole triazolothiadiazine docking ADME organosilicon compounds SILA-409 (Alis-409) SILA-421 (Alis-421) multidrug resistance (MDR) reversal ABCB1 (P-glycoprotein) colon cancer colchicine amide colchicine sulfonamide tubulin inhibitors docking studies crystal structure PROTACs protein degradation IGF-1R Src protein kinase phenylpyrazolopyrimidine enzyme inhibition molecular simulation androgen receptor prostate cancer enzalutamide apalutamide darolutamide triple-negative breast cancer cytotoxicity chrysin analogues flavonoid anticancer compounds |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Altri titoli varianti | Anticancer Agents |
| Record Nr. | UNINA-9910557129103321 |
Chen Qiao-Hong
|
||
| Basel, Switzerland, : MDPI - Multidisciplinary Digital Publishing Institute, 2021 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Inhibiting PARP as a Strategic Target in Cancer
| Inhibiting PARP as a Strategic Target in Cancer |
| Autore | Kristin Zorn |
| Pubbl/distr/stampa | Frontiers Media SA, 2016 |
| Descrizione fisica | 1 electronic resource (97 p.) |
| Collana | Frontiers Research Topics |
| Soggetto non controllato |
DNA reapir
PARP inhibitor Homologous Recombination combination therapy DNA Damage Cancer |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910220059703321 |
|
Kristin Zorn
|
||
| Frontiers Media SA, 2016 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Integrating Clinical and Translational Research Networks-Building Team Medicine
| Integrating Clinical and Translational Research Networks-Building Team Medicine |
| Autore | Salgia Ravi |
| Pubbl/distr/stampa | Basel, Switzerland, : MDPI - Multidisciplinary Digital Publishing Institute, 2021 |
| Descrizione fisica | 1 electronic resource (250 p.) |
| Soggetto topico | Medicine |
| Soggetto non controllato |
renal cell carcinoma
team medicine translational research community practice clinical trials geriatric oncology older adults cancer clinical trials recruitment community team science bladder cancer urothelial carcinoma COVID-19 team-based medicine colorectal cancer precisian medicine academic and community oncology cancer center lung cancer lung cancer screening low-dose CT scans cancer prevention smoking cessation tobacco control national guidelines for screening and prevention pharmaceutical aids to smoking cessation non-small cell lung cancer driver mutations testing rates receptor tyrosine kinases actionable mutations next-generation sequencing fast-and-frugal trees personalized medicine minorities ethnicity race breast cancer research HER2-directed therapy community oncology academic cancer center precision medicine cancer genetics cancer genomics small cell lung cancer immunotherapy epithelial ovarian cancer frontline treatment surgical debulking adjuvant chemotherapy maintenance therapy PARP inhibitor genetics counseling clinical research oropharyngeal cancer concurrent chemoradiation therapy human papillomavirus feeding tube dependency value-based care value-based cancer care oncology pathways Early Recovery After Surgery (ERAS) team-based care oncology medical home integrated cancer care supportive care pathways surgical pathways cancer care plans |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910557124403321 |
|
Salgia Ravi
|
||
| Basel, Switzerland, : MDPI - Multidisciplinary Digital Publishing Institute, 2021 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||